Chennai: Caplin Point Laboratories Limited has announced that its subsidiary, Caplin Steriles Limited, has received an Official Action Indicated (OAI) classification from the United States Food and Drug Administration (USFDA) following an inspection of its injectable and ophthalmic manufacturing facility at Gummidipoondi, Tamil Nadu.

In a regulatory disclosure, the company stated that the US FDA had conducted an unannounced inspection of the facility between August 13 and August 21, 2026. The inspection concluded with 10 observations, which the company described as procedural in nature.

Following the inspection, the US FDA determined the facility’s inspection classification as Official Action Indicated (OAI). The company stated that it received the communication regarding the classification on November 16, 2026.

Despite the regulatory development, Caplin Point Laboratories stated that it does not expect any material impact on its financials or operations as of the date of the disclosure. The company also confirmed that the facility continues to manufacture and supply products.

The company reiterated its commitment to maintaining high standards of quality, current Good Manufacturing Practices (cGMP) and regulatory compliance. It further stated that it would work closely with the US FDA to address the observations and demonstrate the effectiveness and sustainability of the corrective and preventive actions.

Caplin Point Laboratories also assured that it would keep the stock exchanges informed of any further developments related to the matter.

Caplin Point Laboratories Limited is a pharmaceutical company headquartered in Chennai, Tamil Nadu, engaged in pharmaceutical manufacturing and marketing. Its subsidiary, Caplin Steriles Limited, operates in the injectable and ophthalmic pharmaceutical segments, with its manufacturing facility at Gummidipoondi.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .